Loading clinical trials...

A Study of Pulmonary Hypertension Peripheral Limitations | Clinical Trials | Clareo Health

RECRUITINGNA

A Study of Pulmonary Hypertension Peripheral Limitations

Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle Training - The PH Training Trial

NCT05968859•Mayo Clinic

Summary

The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Pulmonary Arterial Hypertension (PAH) Subjects:
•1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
•2. NYHA Class II-IV
•3. LVEF ≥ 40 % within the preceding year.
•4. No hospitalizations due to heart failure in the preceding 30 days.
•5. No recent initiation of pulmonary vasodilator in the last 60 days
•6. Pulmonary arterial hypertension by right heart catheterization (Mean PA pressure ≥ 20 mmHg with PVR\>2 Wood units) with no evidence of heart failure with preserved ejection fraction (exercise PCWP \<25 mm Hg).
•7. Symptomatic PAH patients with plan to undergo exercise RHC for reassessment of exertional symptoms
•2. Healthy Controls:
•1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
+1 more criteria

Exclusion Criteria

•Myocardial infarction, stroke, hospitalization for heart failure, unstable angina pectoris or transient ischemic attack within 30 days prior to the day of screening.
•Planned coronary, carotid, or peripheral artery revascularization.
•Any other condition judged by the investigator to be the primary cause of dyspnea (such as heart failure due to restrictive cardiomyopathy or infiltrative conditions (e.g., amyloidosis), hypertrophic obstructive cardiomyopathy, anemia, or more than moderate mitral or aortic heart valve disease).
•Wheelchair bound or orthopedic inability to exercise
•Chronic hypoxemia with inability to exercise without oxygen supplementation (PAH Subjects) or need for oxygen supplementation (Healthy Controls)
•Skeletal muscle myopathy
•History of rhabdomyolysis
•Participation in any clinical trial of an approved or non-approved device for the treatment of pulmonary hypertension within 30 days before screening.
•Receipt of any investigational medicinal product within 30 days before screening
•Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
+2 more criteria

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

January 2, 2024

Primary Completion Date

March 1, 2028

Completion Date

March 1, 2028

Last Updated

April 8, 2025

Enrollment

ESTIMATED participants

Conditions

Pulmonary Arterial HypertensionHealthy

Interventions

Aerobic Training

BEHAVIORAL

Leg Training

BEHAVIORAL

Contacts

Circulatory Failure Research Team

CONTACT

(507) 255-2200

Yogesh Reddy

CONTACT

(507) 284-3687 Reddy.Yogesh@mayo.edu

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITINGPHASE1/PHASE2

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Pulmonary Hypertension Peripheral Limitations

Inclusion Criteria

Exclusion Criteria

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A New Portable Device for Non-invasive Ventilatory Support

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases